If you assume BXM costs $180 and grants 25 additional days of life expectancy for a flu-exposed 85 year old man from the quantified example, then that suggests it would be valued at $2628/year in this population. Probably one year with comorbidities at 85 is not one QALY, but still I have to imagine that’s drastically above the threshold for US medicine, albeit nowhere close to the cost-effectiveness of the most effective global health charities from a utilitarian perspective.
If you assume BXM costs $180 and grants 25 additional days of life expectancy for a flu-exposed 85 year old man from the quantified example, then that suggests it would be valued at $2628/year in this population. Probably one year with comorbidities at 85 is not one QALY, but still I have to imagine that’s drastically above the threshold for US medicine, albeit nowhere close to the cost-effectiveness of the most effective global health charities from a utilitarian perspective.